Ex-Cedilla CEO Glucksmann explores ‘new frontier’ at Sensorium; R&D chief out at Merck women’s health spinoff Organonnews2023-12-08T10:52:25+00:00December 8th, 2023|Endpoints News|
Sam Waksal’s ROCK2 biotech Graviton hauls in $35M boost from Enavatenews2023-12-07T20:44:11+00:00December 7th, 2023|Endpoints News|
Biden proposal on ‘march-in’ rights would have limited effect on current drug costs, critics saynews2023-12-07T20:27:24+00:00December 7th, 2023|Endpoints News|
Sen. Klobuchar calls out Rising Pharma for price-gouging an old generic drug in shortagenews2023-12-07T20:05:07+00:00December 7th, 2023|Endpoints News|
Physicians are starting to shift pharma sales rep models from push to pull, study findsnews2023-12-07T19:40:57+00:00December 7th, 2023|Endpoints News|
Merck halts trial after Keytruda-Lynparza combo flunks PhIII study in lung cancernews2023-12-07T19:19:34+00:00December 7th, 2023|Endpoints News|
House committee advances key PBM bills in step with Senate counterpartsnews2023-12-07T18:50:55+00:00December 7th, 2023|Endpoints News|
Vanda buys J&J’s multiple sclerosis drug Ponvory for $100Mnews2023-12-07T18:50:40+00:00December 7th, 2023|Endpoints News|
Dantari’s polymer nanoparticle-drug conjugate clears PhI breast cancer hurdle, sparking PhII plansnews2023-12-07T18:14:08+00:00December 7th, 2023|Endpoints News|
Synaffix expands Innovent deal; Recipharm co-develops inhalers; VitriVax gets $5M for vaccine technews2023-12-07T17:38:32+00:00December 7th, 2023|Endpoints News|
